Skip to main content
. 2021 Nov 2;22(21):11909. doi: 10.3390/ijms222111909

Figure 1.

Figure 1

Overview of genetic events linked to treatment resistance strategies in glioblastoma malignancies. Mutagenetic events inducing constitutive (A) PI3K and (B) EGFR activity lead to increased tumor growth, proliferation, metabolism and angiogenesis [21,23,24,31,32,33]. (C) Mutations in substrate-binding active sites of IDH1 and IDH2 impede histone demethylation pathways, altering gene regulation and contributing to tumorigenesis [27,28].